*SCALPSWINGSTRADDLE*

[read_this_n0w]

- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $37.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be $251,250,000.